| 1 |
Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients |
|
|
| Shin-Shin Ho, Tsen-Fang Tsai |
|
| Molecular Diagnosis & Therapy. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis |
|
|
| Rani Soenen, Zhigang Wang, Lynda Grine, Erwin Dreesen, Lisa Schots, Els Brouwers, Paul Declerck, Debby Thomas, Jo Lambert |
|
| Clinical and Experimental Dermatology. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis |
|
|
| Lanmei Lin, Yilun Wang, Xiaonian Lu, Tianxiao Wang, Qunyi Li, Runnan Wang, Jinfeng Wu, Jinhua Xu, Juan Du |
|
| Frontiers in Pharmacology. 2022; 13 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab |
|
|
| Cheng-Ying Chiang,Tsen-Fang Tsai |
|
| Dermatology and Therapy. 2021; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis |
|
|
| T.-F. Tsai |
|
| British Journal of Dermatology. 2021; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment |
|
|
| T.-F. Tsai |
|
| British Journal of Dermatology. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study |
|
|
| K. Reich,A. Körber,U. Mrowietz,M. Sticherling,C. Sieder,J. Früh,T. Bachhuber |
|
| British Journal of Dermatology. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement |
|
|
| Tzong-Yun Ger, Yu-Huei Huang, Rosaline Chung-yee Hui, Tsen-Fang Tsai, Hsien-Yi Chiu |
|
| Therapeutic Advances in Chronic Disease. 2019; 10: 2040622319 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
